Cytosorbents (CTSO) Non-Current Debt (2016 - 2026)

Cytosorbents has reported Non-Current Debt for 10 years, with the latest figure at $10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 27.31% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.3 million (down 27.31% YoY), and the FY2025 full-year result was $16.7 million, up 19.08% from the prior year.
• Non-Current Debt for Q1 2026 stood at $10.3 million, down from $16.7 million in the prior quarter.
• The five-year high for Non-Current Debt was $16.7 million in Q4 2025, with the low at $1.9 million in Q1 2024.
• Historically, Non-Current Debt has averaged $10.0 million across 5 years, with a median of $13.7 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Debt plunged 49.14% — and 2025, when it jumped 635.61%.
• Cytosorbents' Non-Current Debt stood at $5.0 million in 2022, then sank by 49.14% to $2.5 million in 2023, then jumped by 450.4% to $14.0 million in 2024, then gained by 19.08% to $16.7 million in 2025, then tumbled by 38.12% to $10.3 million in 2026.
• The last three Non-Current Debt figures came in at $10.3 million (Q1 2026), $16.7 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.